Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Tipo del documento
Intervalo de año
1.
researchsquare; 2024.
Preprint en Inglés | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-4186317.v1

RESUMEN

Immune imprinting or original antigenic sin (OAS) originally referred to a phenomenon of suboptimal immune response to a repeat exposure to a virus that was antigenically distinct from the original virus infection. OAS has been implicated in higher mortality in young people during the 2009-10 H1N1 pandemic where the elderly (H1N1 exposure in childhood) appeared relatively well protected compared to younger individuals whose first influenza infection was not H1N1. Immune imprinting is part of a rapid recall system and is highly effective against a slowly evolving virus (drifting) but not antigenically shifting viruses such as influenza and SARS CoV-2. As predicted by OAS, suboptimal neutralization responses to the highly divergent SARS-COV-2 lineage Omicron have been observed in animal models and individuals previously vaccinated with primary course of ancestral (Wu-1) vaccine. Due to the rapid scale up of vaccine before emergence of the antigenically distinct Omicron variant, it is unknown whether immunological imprinting for occurs in the context of SARS-COV-2 infection itself. We longitudinally assessed humoral responses to primary two dose Ad26.COV2.S Wu-hu-1 based vaccination in a Nigerian population following the global emergence of Omicron. At study entry in Jan 2023, we found 93% and 58% of pre-vaccination participants previously exposed to ancestral Wu-1 and Omicron virus respectively by anti-N IgG and anti-receptor binding domain (RBD) IgG Wu-1 and Omicron -specific antibodies. In participants with no evidence of prior exposure to Omicron, neutralisation against Wu-1 was significantly higher than Omicron variants as expected. However, serum neutralisation titres in participants who were anti-RBD Omicron IgG positive were paradoxically 2-fold lower for Omicron BA.1 as compared to Wu-1. This is clear evidence for imprinted immunity from the ancestral pre-omicron lineage viruses, and remarkably these old responses to Wu-1 were able to dominate over more recent, likely multiple, Omicron lineage infections. Furthermore, in these participants with prior exposure to Omicron and evidence of imprinting, we observed that further Omicron infection and Wu-1 based vaccine was associated with boosting of responses across variants with equalisation of neutralisation titres for Wu-1 and Omicron variants. However, omicron responses did not surpass ancestral responses, suggesting persistence of imprinting and only partial mitigation. Although neutralization responses at high titres were observed post dose 1 vaccination against ancestral and Omicron variants BA.1, BA.2, BA.4 in nearly all participants, neutralisation against the highly immune evasive XBB recombinant variant remained substantially lower, with a second vaccine dose providing very modest boosting. These data highlight immune imprinting against SARS-CoV-2 prior to vaccination and its persistence thereafter. In present day unvaccinated populations where serum neutralisation responses to pre-Omicron variants dominate, use of an omicron variant based vaccine should be used in preference to Wu-1 based vaccine to override imprinting and provide broader protection for vulnerable populations such as the elderly or those with compromised immunity.


Asunto(s)
Infecciones Tumorales por Virus , COVID-19 , Gripe Humana
2.
Idowu Bolade Olawoye; Paul Eniola Oluniyi; Edyth Parker; Judith Uche Oguzie; Jessica Nnenna Uwanibe; Tolulope Adeyemi Kayode; Fehintola Victoria Ajogbasile; Testimony Jesupamilerin Olumade; Philomena Eromon; Priscilla Abechi; Tope Sobajo; Chinedu Ugwu; George Uwem; Femi Ayoade; Kazeem Akano; Oluwasemilogo Oluwasekunolami Akinlo; Julie Oreoluwa Akin-John; Nicholas Oyejide; Olubukola Ayo-Ale; Benjamin Adegboyega; Grace Chizaramu Chukwu; Ayomide Adeleke; Grace Opemipo Ezekiel; Farida Brimmo; Olanrewaju Odunyemi Fayemi; Iyanuoluwa Fred-Akintunwa; Ibrahim F. Yusuf; Testimony Oluwatise Ipaye; Oluwagboadurami John; Ahmed Iluoreh Muhammad; Deborah Chisom Nwodo; Olusola Akinola Ogunsanya; Johnson Okolie; Abolade Esther Omoniyi; Iyobosa Beatrice Omwanghe; Oludayo Oluwaseyi Ope-ewe; Shobi Otitoola; Kemi Adedotun-Suleiman; Courage Philip; Mudasiru Femi Saibu; Ayotunde Elijah Sijuwola; Christabel Anamuma Terkuma; Augustine Abu; Johnson Adekunle Adeniji; Moses Olubusuyi Adewunmi; Olufemi Oluwapelumi Adeyemi; Rahaman Ahmed; Anthony Ahumibe; Anthony Nnennaya Ajayi; Olusola Akanbi; Olatunji Akande; Monilade Akinola; Afolabi Akinpelu; George Akpede; Ekanem Anieno; Antjony E. Atage; Oyeronke Ayansola; Marycelin Baba; Olajumoke Babatunde; Bamidele Soji Oderinde; Ebo Benevolence; Osiemi Blessing; Mienye Bob-Manuel; Andrew Bock-Oruma; Aire Chris; Chimaobi Chukwu; Funmi Daramola; Adomeh Donatus; Rosemay Duruihuoma; Yerumoh Edna; Matthew Ekeh; Erim Ndoma; Richard Ewah; Akinwumi Fajola; Enoch Olowatosin Fakayode; Adeola Fowotade; Galadima Gadzama; Daniel Igwe; Odia Ikponmwosa; Rafiu Olasunkanmi Isamotu; Agbukor Jacqueline; Aiyepada John; Julie Johnson Ekpo; Ibrahim Kida; Nwando Mba; Airende Micheal; Mirabeau Youtchou Tatfeng; Worbianueri Beatrice Moore-Igwe; Anietie Moses; Okonofua Naregose; Nsikak-Abasi Ntia; Ifeanyi Nwafor; Elizabeth Odeh; Ephraim Ogbaini; Kingsley Chiedozie Ojide; Sylvanus Okogbenin; Peter Okokhere; Sylvanus Okoro; Azuka Okwuraiwe; Olisa Olasunkanmi; Oluseyi Olayinka; Adesuyi Omoare; Ewean Chukwuma Omoruyi; Hannah E. Omunakwe; Emeka Onwe Ogah; Chika Onwuamah; Venatious Onyia; Akhilomen Patience; Ebhodaghe Paulson; Omiunu Racheal; Esumeh Rita; Giwa Rosemary; Joseph Shaibu; Joseph Shaibu; Ehikhametalor Solomon; Ngozi Ugwu; Collins Nwachi Ugwu; Kingsley Ukwuaja; Zara Wudiri; Nnaemeka Ndodo; Brittany Petros; Bronwyn Mcannis; Cyril Oshomah; Femi Oladiji; Katherine J. Siddle; Rosemary Audu; Babatunde Lawal Salako; Stephen Schaffner; Danny Park; Ifedayo Adetifa; Chikwe Ihekweazu; Oyewale Tomori; Anise Nkenjop Happi; Onikepe Folarin; Kristian G. Andersen; Pardis C. Sabeti; Christian Tientcha Happi.
medrxiv; 2022.
Preprint en Inglés | medRxiv | ID: ppzbmed-10.1101.2022.09.24.22280269

RESUMEN

Identifying the dissemination patterns and impacts of a virus of economic or health importance during a pandemic is crucial, as it informs the public on policies for containment in order to reduce the spread of the virus. In this study, we integrated genomic and travel data to investigate the emergence and spread of the B.1.1.318 and B.1.525 variants of interest in Nigeria and the wider Africa region. By integrating travel data and phylogeographic reconstructions, we find that these two variants that arose during the second wave emerged from within Africa, with the B.1.525 from Nigeria, and then spread to other parts of the world. Our results show how regional connectivity in downsampled regions like Africa can often influence virus transmissions between neighbouring countries. Our findings demonstrate the power of genomic analysis when combined with mobility and epidemiological data to identify the drivers of transmission in the region, generating actionable information for public health decision makers in the region.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA